X

Trial Profile

Evaluation of the Efficacy and Safety of Rivaroxaban (BAY 59-7939) for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Warfarin
Indications Stroke; Thromboembolism
Focus Adverse reactions; Therapeutic Use
Acronyms J-ROCKET-AF
Sponsors Bayer

Most Recent Events

29 Aug 2016 Results published in Bayer media release
07 Apr 2014 Results from a sub-group analysis published in the Circulation Journal.
27 Jul 2011 Primary endpoint "Stroke and thromboembolism-event-rate has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com